Orphan Drugs
Middle East · 2 shared keywords
Updated
Reviewed by Vidhi Upadhyay
Middle East AI in Drug Repurposing Market Industry Trends and Forecast to 2034: Segmented by (Approach, Indication, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$134.7 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $20.5 Mn | — | — |
| 2025 (base) | $25.2 Mn | +$4.7 Mn | — |
| 2026 (forecast) | $30.9 Mn | +$5.7 Mn | +22.8% |
| 2027 (forecast) | $38.0 Mn | +$7.1 Mn | +50.8% |
| 2028 (forecast) | $46.6 Mn | +$8.7 Mn | +85.2% |
| 2029 (forecast) | $57.3 Mn | +$10.6 Mn | +127.4% |
| 2030 (forecast) | $70.3 Mn | +$13.1 Mn | +179.2% |
| 2031 (forecast) | $86.4 Mn | +$16.0 Mn | +242.9% |
| 2032 (forecast) | $106.0 Mn | +$19.7 Mn | +321.1% |
| 2033 (forecast) | $130.2 Mn | +$24.2 Mn | +417.1% |
| 2034 (forecast) | $159.9 Mn | +$29.7 Mn | +535% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $25.2 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $159.9 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 22.8% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Also called | Artificial Intelligence in Drug Repurposing |
| Segments | Approach and indication (see all) |
| Key players | BenevolentAI, Healx, Insilico Medicine, Recursion Pharmaceuticals, Every Cure (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
AI in drug repurposing searches data to find new uses for existing medicines, cutting the time and cost of development.
Key segments of the AI in Drug Repurposing market include approach (Knowledge Graphs, Machine Learning on Omics and Real-World Data Mining) and indication (Rare Diseases, Oncology and Infectious Diseases).
Advances in machine learning and large language models, more digital health data, clinician shortages and pressure to cut costs are driving the AI in Drug Repurposing market. Health systems are moving from pilots to wider use.
Generative AI, automation of paperwork and AI tools approved as medical devices give the AI in Drug Repurposing market strong growth, including in emerging health systems.
Concerns about accuracy, bias, privacy and liability, along with unclear regulation and the cost of fitting AI into clinical workflows, hold back the AI in Drug Repurposing market.
The AI in Drug Repurposing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medicines are approved by SFDA (Saudi Arabia)[1], EDE (UAE)[2], Ministry of Public Health (Qatar)[3] and Ministry of Health (Israel)[4]. How care is paid for in some of these countries: free public care and CHI-regulated insurance (Saudi Arabia)[5], mandatory health insurance (UAE)[6], public care and compulsory insurance (Qatar)[3] and four health funds (Israel)[4].
[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.
[2] Emirates Drug Establishment. Checked 14 Nov 2026.
[3] Ministry of Public Health, Qatar. Checked 19 Nov 2026.
[4] Israel Ministry of Health. Checked 19 Nov 2026.
[5] Council of Health Insurance. Checked 14 Nov 2026.
[6] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for AI in Drug Repurposing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Middle East.
What doctors and scientists are doing in AI in Drug Repurposing right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Middle East · 2 shared keywords
Middle East · 1 shared keyword
Middle East · 1 shared keyword
Middle East · 1 shared keyword
Middle East · 1 shared keyword
Middle East · 1 shared keyword
Digital Health · Middle East
Digital Health · Middle East
Digital Health · Middle East
Digital Health · Middle East
Digital Health · Middle East
Digital Health · Middle East